Announced details
Uterine fibroids; endometriosis
Statistically significant improvement over placebo in the primary endpoint
Relugolix monotherapy (レルミナ tablets) is widely used in clinical practice for the indications of uterine fibroids and endometriosis.
Asuka Pharmaceutical in-licensed the product from Takeda Pharmaceutical Company Limited and entered into a license agreement granting it exclusive development and commercialization rights in Japan for uterine fibroids and endometriosis.
Head office: Chuo-ku, Osaka. Other details: not disclosed.
Asuka Pharmaceutical head office: Minato-ku, Tokyo. Takeda Pharmaceutical Company Limited head office: Chuo-ku, Osaka.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Relugolix combination product (AKP-022; generic names: relugolix, estradiol, norethindrone acetate) |
| Counterparty | Takeda Pharmaceutical Company Limited |
| Counterparty overview | Head office: Chuo-ku, Osaka. Other details: not disclosed. |
| Relationship with the Company | Asuka Pharmaceutical in-licensed the product from Takeda Pharmaceutical Company Limited and entered into a license agreement granting it exclusive development and commercialization rights in Japan for uterine fibroids and endometriosis. |
| Contract Date | 27 September 2021 (uterine fibroids); 31 May 2024 (endometriosis) |
| Applicable area | Uterine fibroids; endometriosis |
| Location | Asuka Pharmaceutical head office: Minato-ku, Tokyo. Takeda Pharmaceutical Company Limited head office: Chuo-ku, Osaka. |
| Quantitative Effects | Statistically significant improvement over placebo in the primary endpoint |
| Usage history | Relugolix monotherapy (レルミナ tablets) is widely used in clinical practice for the indications of uterine fibroids and endometriosis. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The product is being developed to combine relugolix with an estrogen and a progestin, making long-term administration possible for the first time.